Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.
Federated Hermes Inc. boosted its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) by 14.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,085,139 shares of the company's stock after buying an additional 134,206 shares during the period. Federated Hermes Inc. owned 1.90% of Zentalis Pharmaceuticals worth $30,492,000 as of its most recent SEC filing.
联合爱马仕公司在最近提交给美国证券交易委员会的信息中称，该公司在第二季度将其在纳斯达克(Sequoia PharmPharmticals，Inc.)股票的持仓量提高了14.1%。该公司持有1,085,139股该公司股票，在此期间又购买了134,206股。据联合爱马仕最近提交的美国证券交易委员会申请文件显示，该公司持有Zentalis PharmPharmticals 1.90%的股份，价值30,492,000美元。
Several other institutional investors also recently added to or reduced their stakes in the company. Amundi acquired a new position in Zentalis Pharmaceuticals during the second quarter worth approximately $143,000. Legal & General Group Plc grew its stake in shares of Zentalis Pharmaceuticals by 38.1% in the 2nd quarter. Legal & General Group Plc now owns 35,491 shares of the company's stock valued at $998,000 after purchasing an additional 9,791 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Zentalis Pharmaceuticals by 49.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 397,570 shares of the company's stock valued at $11,171,000 after purchasing an additional 132,324 shares during the last quarter. Woodline Partners LP grew its stake in shares of Zentalis Pharmaceuticals by 344.9% in the 2nd quarter. Woodline Partners LP now owns 181,272 shares of the company's stock valued at $5,094,000 after purchasing an additional 140,524 shares during the last quarter. Finally, Thrivent Financial for Lutherans purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $890,000.
其他几家机构投资者最近也增持或减持了该公司的股份。Amundi在第二季度收购了Zentalis制药公司的一个新头寸，价值约为14.3万美元。Legal&General Group Plc在第二季度增持了Zentalis PharmPharmticals的股份38.1%。Legal&General Group Plc现在拥有该公司35,491股股票，价值99.8万美元，上个季度又购买了9,791股。高盛股份有限公司在第二季度增持了森特里斯制药49.9%的股份。高盛股份有限公司在上个季度增持了132,324股后，目前持有397,570股该公司股票，价值11,171,000美元。Woodline Partners LP在第二季度增持了Zentalis制药公司的股份，增幅为344.9%。Woodline Partners LP现在拥有181,272股该公司的股票，价值5094,000美元，在上个季度又购买了140,524股。最后，Thrient Financial for Lutherans在第二季度购买了新的Zentalis制药公司股票，价值约89万美元。
Zentalis Pharmaceuticals Stock Performance
Zentaris制药类股表现
ZNTL opened at $19.38 on Friday. The business's fifty day moving average is $21.96 and its two-hundred day moving average is $24.96. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -4.11 and a beta of 1.80. Zentalis Pharmaceuticals, Inc. has a one year low of $17.33 and a one year high of $85.95.
ZNTL上周五开盘报19.38美元。该业务的50日移动均线切入位为21.96美元，200日移动均线切入位为24.96美元。该公司市值为11.1亿美元，市盈率为-4.11倍，贝塔系数为1.80。Zentalis PharmPharmticals，Inc.的一年低点为17.33美元，一年高位为85.95美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Insiders Place Their Bets
内部人士下注
In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of the business's stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $22.77, for a total transaction of $284,625.00. Following the sale, the president now directly owns 372,011 shares in the company, valued at $8,470,690.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 50,000 shares of company stock worth $1,153,375. 19.90% of the stock is owned by corporate insiders.
另有消息称，总裁·卡姆·加拉格尔在11月15日星期二的一次交易中出售了该公司12,500股票。该股以22.77美元的平均价格出售，总成交金额为284,625.00美元。出售后，总裁现在直接持有该公司372,011股，价值8,470,690.47美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过美国证券交易委员会网站。在过去的90天里，内部人士出售了5万股公司股票，价值1,153,375美元。19.90%的股份由企业内部人士持有。
About Zentalis Pharmaceuticals
关于Zentaris制药公司
(Get Rating)
(获取评级)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Zentalis制药公司是一家临床阶段的生物制药公司，专注于发现和开发用于治疗各种癌症的小分子疗法。它的主要候选产品包括WEE1的抑制剂ZN-c3，这是一种蛋白质酪氨酸激酶，正处于治疗晚期实体肿瘤的第二阶段临床试验；作为单一疗法治疗晚期实体肿瘤的第1/2阶段临床试验，以及正在进行的与铂耐药卵巢癌患者的联合化疗的1b阶段临床试验；以及肿瘤不可知的、可预测的生物标记物的第二阶段单一治疗试验。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- 免费获取StockNews.com关于Zentalis制药的研究报告(ZNTL)
- 拖拉机库存能否突破杯柄收购点？
- 现在不是购买Lennar的时候，但时机即将到来
- 马伦汽车公司改变游戏规则的消息
- 通货膨胀和能源危机是两列相撞的货运列车--以下是如何做好准备的
- 企业产品合作伙伴是否得到公平评价？
Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating).
想看看其他对冲基金持有ZNTL吗？访问HoldingsChannel.com以获取Zentalis制药公司(纳斯达克代码：ZNTL-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Zentaris制药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Zentalis制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。